Skip to content

Author

M. Peluso

We have 8 of 289 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Innate immune imprints shape HIV-1 reservoir cell persistence during long-term antiretroviral therapy

Host immune responses that can target and eliminate HIV-1 reservoir cells during suppressive antiretroviral therapy are poorly understood. Here, analyzing over 6,000 proviral DNA amplicons from 104 individuals on long-term antiretroviral therapy, we found that carriers of HLA-C2 allotypes, which promote NK cell educati...

Toong Seng Tan, Wei-Wei Sun, Ce Gao et al. · 2 citations
Open access Sep 2026

SARS-CoV-2-specific monoclonal antibody AER002 in Long COVID: an exploratory randomized phase 2a mechanistic trial

Persistence of SARS-CoV-2 has been proposed as a biological driver of Long COVID, a disabling chronic illness with no proven treatments. We conducted an exploratory, placebo-controlled, double-blind, 2:1 randomized mechanistic trial (NCT05877508) of the SARS-CoV-2-specific monoclonal antibody AER002 in 36 participa...

M. Peluso, Dylan Ryder, T. Dalhuisen et al. · 0 citations
Open access Sep 2026

An altered B cell compartment distinguishes low antibody responders among people with HIV

Chronic HIV infection can leave persistent immune dysregulation despite effective antiretroviral therapy (ART), but how this altered immune landscape affects antibody induction and durability after antigen exposure remains unclear. We used SARS-CoV-2 infection and vaccination as a model of humoral immunity to a novel a...

Karli R. Redinger, Samuel B. Warner, A. Jamal et al. · 0 citations
Open access Sep 2026

A mechanistic basis for CD8+ T cell expansion sensitivity as a predictor of HIV post-treatment control

The results provide a mechanistic explanation why both Ki-67+ responding CD8+ T cells and their TCF-1-expressing subset predict post-treatment control, linking clinical correlation to its underlying cause and highlighting Ki-67 and TCF-1 as potential early biomarkers of HIV immunotherapy success.

Tin Phan, Nicole Pagane, Jasmine A. F. Kreig et al. · 0 citations
Aug 2026

Multiomic and Spatial Profiling of Colorectal Tissue Reveals Viral Persistence and Immune Dysregulation in Long COVID

A tissue-based transcriptional environment in which SARS-CoV-2 activates innate myeloid immune signaling, driving chronic inflammation while simultaneously downregulating pathways responsible for immune-mediated clearance of infected cells is identified, including antigen presentation, phagocytosis, cytotoxic immune ce...

B. LaFranchi, David P. Maison, J. Vinden et al. · 0 citations
Sep 2026

CD4 Count and CD4/CD8 Ratio Impact Antibody Responses to COVID-19 mRNA Booster Vaccination in People with HIV on Suppressive ART.

CD4+ T cell count influences antibody persistence, while the CD4/CD8 ratio affects initial antibody magnitude and Tfh cell frequencies, highlighting complementary roles in shaping vaccine responses in PLWH.

Roser Navarro-Soler, M. J. Heise, T. Dalhuisen et al. · 0 citations
Open access Aug 2026

HIV DNA and transcription before and after ART in natural controllers compared to noncontrollers

It is found that natural control was associated with mechanisms that reduce levels of total HIV DNA and the HIV promoter regions to below the levels seen in ART-treated noncontrollers (NC), resulting in lower total levels of most HIV transcripts.

Sun Jin Kim, Julie Janssens, Cordelia Isbell et al. · 0 citations
Open access Aug 2026

Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.

BACKGROUND Post-acute sequelae of SARS-CoV-2 infection, more commonly known as long COVID, has emerged as a major health problem. The pathogenesis of long COVID is unknown, but among the leading hypotheses is viral persistence. We aimed to investigate whether the use of the SARS-CoV-2 antiviral nirmatrelvir-ritonavir i...

L. Baden, N. Shah, Sean T. H. Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.